RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback